Cohort Profile

Cohort profile: The Cohorts Consortium of Latin America and the Caribbean (CC-LAC)

Cohorts Consortium of Latin America and the Caribbean (CC-LAC)†

Corresponding author. J Jaime Miranda, CRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Address: Av. Armendáriz 497, Lima 18, Peru. E-mail: jaime.miranda+CCLAC@upch.pe
†Authors are listed in the supplementary material, available at Supplementary date at IJE online.

Editorial decision 23 March 2020; Accepted 3 April 2020

Why was the cohort set up?
Latin America and the Caribbean (LAC) are characterized by much diversity in terms of socio-economic status, ecology, environment, access to health care,1,2 as well as the frequency of risk factors for and prevalence or incidence of non-communicable diseases;3–7 importantly, these differences are observed both between and within countries in LAC.8,9 LAC countries share a large burden of non-communicable (e.g. diabetes and hypertension) and cardiovascular (e.g. ischaemic heart disease) diseases, with these conditions standing as the leading causes of morbidity, disability and mortality in most of LAC.10–12 These epidemiological estimates—e.g. morbidity—cannot inform about risk factors or risk prediction, which are relevant to identify prevention avenues. Cohort studies, on the other hand, could provide this evidence. Pooled analysis, using data from multiple cohort studies, have additional strengths such as increased statistical power and decreased statistical uncertainty.13 LAC cohort studies have been under-represented,14 or not included at all,15–17 in international efforts aimed at pooling data from multiple cohort studies. We therefore set out to pool data from LAC cohorts to address research questions that individual cohort studies would not be able to answer.

Drawing from previous successful regional enterprises (e.g. Asia Pacific Cohort Studies Collaboration),18,19 we established the Cohorts Consortium of Latin America and the Caribbean (CC-LAC). The main aim of the CC-LAC is to start a collaborative cohort data pooling in LAC to examine the association between cardio-metabolic risk factors (e.g. blood pressure, glucose and lipids) and non-fatal and fatal cardiovascular outcomes (e.g. stroke or myocardial infarction). In so doing, we aim to provide regional risk estimates to inform disease burden metrics, as well as other ambitious projects including a cardiovascular risk score to strengthen cardiovascular prevention in LAC.

Initial funding has been provided by a fellowship from the Wellcome Trust Centre for Global Health Research at Imperial College London (Strategic Award, Wellcome Trust–Imperial College Centre for Global Health Research, 100693/Z/12/Z). Additional funding is being provided by an International Training Fellowship from the Wellcome Trust (214185/Z/18/Z). At the time of writing, the daily operations and pooled database are hosted at Imperial College London, though a mid-term goal is to transfer this expertise and operations to LAC. The collaboration relies fundamentally on a strong regional network of health researchers and practitioners.

Who is in the cohort?
We have harmonized and pooled approximately population-based cohort data on cardio-metabolic risk factors and outcomes, i.e. participants were not recruited based on disease (e.g. cohort of stroke survivors) or risk factor (e.g. cohort of smokers) history. Data have been collated by the CC-LAC, a LAC network of health researchers and practitioners. The database was collated using multiple data identification sources. First, we accessed publicly available cohort data through each
Among those cohorts we currently have pooled, there are two multi-country studies: Centro de Excelencia en Salud Cardiovascular para América del Sur (CESCAS) Cohort (Argentina, Chile and Uruguay)24 and the 10/66 Study (Cuba, Dominican Republic, Peru, Venezuela, Mexico and Puerto Rico),25,26 whereas the other cohort studies were based in only one country. The largest sample size is with The Mexican Teachers’ Cohort (Table 2).22 A list of all pooled cohorts along with supporting references is presented in Supplementary data pp. 03–06, available as Supplementary data at IJE online.

The aforementioned 7 cohorts that have not been pooled because cardiovascular outcomes are not yet available include: CRONICAS Cohort Study (Peru),27 Mexican Heart & Aging Study (Mexico),28 Puerto Rican Elderly Health Conditions (Puerto Rico),29 Costa Rican Longevity and Healthy Aging Study (CRELES) 1945–1955 Retirement Cohort (Costa Rica),30 Influence of Biopsychosocial Factors on the Survival of the Elderly in Northeast Brazil—A Prospective Study (Brazil),31 Baependi Heart Study (Brazil)32 and MONICA-VITÓRIA study (Brazil).33

The pooled dataset including all cohorts is not designed to be fully representative of the populations of regions and countries in which they have been conducted. Nevertheless, the results provided by this consortium will be informative for most of the LAC region, where large, longitudinal and multi-country studies remain insufficient in the field of cardiovascular diseases risk prediction. This consortium aims to advance the regional scientific evidence by overcoming the limitations of individual cohorts, e.g. studies with small sample size or limited number of events, while building upon a strong collaborative network of investigators.

How often have they been followed up?

The CC-LAC has pooled the baseline assessment and the latest follow-up available for each cohort; for the purpose of this consortium all subjects have been followed once, i.e. at baseline and one follow-up. All pooled individuals have the outcomes of interest, either non-fatal or fatal cardiovascular events (or censored). At the time of the first data lock, the 32 pooled cohorts had a mean follow-up time to the first cardiovascular non-fatal/fatal event of 8.50 (median = 8.80) years, ranging from <1.0 to 27.7 years.

Figure 2 shows the number of cohort studies and the percentage of the pooled sample size at baseline. Most pooled cohorts started in the 2000s. Furthermore, 15.7% (n = 27 409) of the pooled sample had <5 years of follow-up, 59.3% (n = 103 254) between 5 and 9 years and 25.0% (n = 43 517) >10 years of follow-up.
What has been measured?

Table 1 shows the number of observations per pooled cardio-metabolic risk factor. In addition to these variables, some cohorts have collected additional anthropometric measurements (e.g. waist/hip circumference or skinfold thickness) and laboratory data (e.g. Glycated hemoglobin (HbA1c), triglycerides, low-density lipoprotein (LDL)-cholesterol). Table 2 depicts the cardio-metabolic risk factors available across the pooled cohorts, and Supplementary data pp. 17–18, available as Supplementary data at IJE online, show further information on these variables at follow-up rounds. In addition to clinical cardio-metabolic risk factors, we have pooled two relevant socio-demographic indicators: place of residence (urban or rural) and schooling (years of education).

Two outcomes of interest have been harmonized and pooled, these are non-fatal and fatal cardiovascular events: haemorrhagic and ischaemic stroke, myocardial infarction (including revascularization), and mortality due to these conditions, as well as sudden death. Where relevant, these outcomes have been adjudicated or extracted from reliable sources, such as clinical records or death registries. Details on the ascertainment methods of these outcomes are provided in Supplementary data pp. 8–16, available as Supplementary data at IJE online.

At the time of the first datalock, data from 174 180 individuals have been pooled: 171 937 (98.7%) have complete follow-up or were censored (e.g. lost-to follow-up or death by other causes), 578 (0.3%) have had a first non-fatal cardiovascular event and 1665 (1.0%) have experienced a fatal cardiovascular event (Table 1).

What has it found? Key findings and publications

This is the first of a series of anticipated outputs and therefore constitutes a key initial publication to provide a general overview of this regional long-needed endeavour. This cohort profile aims to inform the international research and clinical community about our ongoing efforts and inform them of our anticipated forthcoming outcomes. Our ongoing work includes: (i) age-specific risk estimates of cardio-metabolic risk factors on cardiovascular non-fatal and fatal outcomes; (ii) comparative risk assessment of current versus ideal levels of cardio-metabolic risk factors based on regional age-specific risk estimates and survey data; and (iii) a novel risk score for cardiovascular events based on LAC hazard estimates, and country-specific re-calibration with LAC population-based estimates of risk factors. Although other relevant efforts have
provided cardiovascular risk charts for LAC, they all relied on hazard estimates from cohorts outside LAC which may not accurately apply to LAC populations.

Besides scientific publications and other relevant outputs, CC-LAC has found that several cohort studies have been conducted in LAC and provide strong data to advance the knowledge of cardiovascular health in LAC. Probably, these cohort studies were not included in previous international cohort data pooling efforts because of language barriers or because LAC cohorts are rather young, i.e. started mostly in the 2000s. Moreover, CC-LAC has demonstrated that it is feasible to conduct a large-scale cohort data pooling effort across LAC. We encourage other research groups working in different fields across health sciences (e.g. infectious diseases, climate change and maternal/child health) to also embark on similar efforts.

**What are the main strengths and weaknesses?**

The main strength of the CC-LAC is its regional scope and the large sample size. As discussed before (see ‘Why was the cohort set up?’ section), LAC has not participated in other global cohort data-pooling efforts to study cardiovascular risk factors and outcomes, leaving room to study cardio-metabolic risk estimates in this region. This work is therefore the first-ever cohort data-pooling study in LAC, which will ultimately produce solid evidence to guide clinical and public health practice in LAC. Previous data-pooling efforts in LAC have only focused on cross-sectional or survey data, and have shown relevant differences in relation to high-income countries. CC-LAC will complement and move these efforts to the next level, achieving larger impact in LAC healthcare, practice, research and policy. Moreover, the fact that most of the pooled cohorts have begun in recent years is also a strength. They will provide evidence based on contemporary estimates, reflecting the present epidemiological scenario. The CC-LAC has managed to harmonize key cardio-metabolic risk factors that were measured following consistent protocols, e.g. repeated blood pressure measurements or standard laboratory methods for biomarkers. Lastly, with the large sample size, other relevant outcomes, such as diabetes risk, may also be investigated.

Data pooling comes with methodological challenges. Understanding the heterogeneity among cohorts in terms of population and sampling methodology, as well as variables collection and ascertainment, is relevant to find the best way to pool and harmonize available cohort data. Additional sources of heterogeneity, such as different levels of non-response rates, would be a limitation of any cohort data-pooling project. Future results should be interpreted considering all this and other limitations specific to each research question.

Like other cohort pooling studies, among the weaknesses we should point out the heterogeneity in the definition of cardiovascular events. Although pooled cohorts have followed adjudication processes, or these outcomes were based on death certificates, data were sometimes registered as 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) codes or in broader categories (e.g. cardiovascular deaths). This prevents us from studying some specific outcomes, such as haemorrhagic versus ischaemic stroke. This is not a criticism on our cohorts, but a call to health and vital registries authorities as well as science funders in LAC. Opportunities for additional follow-up rounds of established cohort studies, or to conduct follow-up rounds of large projects that may have been initiated as cross-sectional surveys could be supported. In this regard, for example, the PERU MIGRANT Study was established as a cross-sectional project, though
Table 2. Available cardio-metabolic risk factors across collaborating cohorts; further details about available variables at follow-up are presented in Supplementary data pp. 17–18, available as Supplementary data at IJE online

| Country          | Sample size | Reach City | Anteplante, Santiago | The Madrid (Spain) | Caracas (Venezuela) | Caracas (Venezuela) | The Colombian (COLOFEN) | The Mexican Health & Aging Study | The Mexican Men’s Cohort Study | The Mexican Women’s Cohort Study | The Mediterranean Men’s Cohort Study | The Mediterranean Women’s Cohort Study | The Puerto Rican Heart Health Program | The Puerto Rican Health Outcomes Cohort Study | GBF-Cay | CIESAS | REDES | REDES | REDES | REDES | REDES | REDES | REDES | REDES | REDES | REDES | REDES | 10/02 Dementia Study |
|------------------|-------------|------------|----------------------|-------------------|--------------------|--------------------|----------------------|--------------------------|-------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|------------------------------------------------|------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| **Socio-demographics** |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Age              |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Sex              |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Location (urban/ rural) |     |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Education (years) |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| **Clinical evaluation** |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Blood pressure   |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Weight           |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Height           |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Waist            |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Ht/Ht             |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| **Laboratory**    |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Total cholesterol |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| HDL cholesterol  |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| LDL cholesterol  |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Triglycerides    |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| HbA1c            |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| **Health history (self reported)** |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Hypertension diagnosis |         |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Hypertension drugs |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Diabetes diagnosis |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Diabetes drugs   |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| **Health-related behaviours** |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Alcohol consumption |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Current smoker   |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| **Cardiovascular outcomes** |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Non-fatal        |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |
| Fatal            |             |            |                      |                   |                    |                    |                      |                          |                               |                                 |                                 |                                 |                                 |                                                                                                     |            |              |              |              |              |              |              |              |              |              |              |              |              |              |

*Self-reported height/weight.

CESCAS, Centro de Excelencia en Salud Cardiovascular para América del Sur; GEFA-HT-UY, GENotipo, Fenotipo y Ambiente de la HiperTensión Arterial en Uruguay; NP, not pooled yet.
with support from UPCH and intentional funders (e.g. GloCal Health Fellowship Program from the University of California Global Health Institute), the investigators managed to conduct two follow-up rounds. In Jamaica, the Jamaica Healthy Lifestyle Study, a repeated cross-sectional survey on non-communicable diseases risk factors has recently received National Institutes of Health (R01) funding to expand the cross-sectional work into a true longitudinal cohort. Finally, another limitation is the relative scarcity of data from the Caribbean. The CC-LAC will provide relevant information pooling all available cohorts from this region. We strongly believe that this cohort profile, and forthcoming publications, will allow us to identify additional sources from this region or will stimulate interest among researchers from the Caribbean to conduct local and multi-country cohort studies.

The lack of novel or more sophisticated cardio-metabolic risk factors may be a limitation as well; these could include inflammation markers (e.g. high-sensitive C-reactive protein) or lipid biomarkers (e.g. apolipoproteins). Some of the pooled cohort studies have, nevertheless, stored blood samples from their baseline rounds. We strongly believe that CC-LAC will enhance visibility of LAC cohort studies and promote regional collaboration. In the future, additional risk factors may be measured in some cohorts or new follow-up rounds may be conducted to overcome current limitations.

Can I get hold of the data? Where can I find out more?

Data availability will be prioritized among CC-LAC members. New LAC cohort studies are welcomed to join the CC-LAC. Expressions of interest in additional collaborations will be received and handled by the CC-LAC steering committee. For further details on our work, please contact the corresponding author.

Profile in a nutshell

- We set up the Cohorts Consortium of Latin America and the Caribbean (CC-LAC) to fill knowledge gaps in cardiovascular medicine and prevention relevant to LAC. The CC-LAC is uniquely positioned to study long-term effects of cardio-metabolic risk factors and outcomes in LAC, providing relevant and strong local evidence as well as pragmatic tools to advance clinical medicine and public health in LAC.
- A total of 32 cohorts have been pooled, with an additional 7 cohorts that have not documented cardiovascular outcomes yet. Three of the 32 cohorts started before 1990 (6.4% of pooled sample), 9 in the 1990s (7.0%), 15 in the 2000s (80.5%) and 5 since 2010 (6.1%) for a total of 174 180 participants at baseline. Precisely 16.9% of the participants are men, and the mean age is 47.6 (46 in women and 55 in men) years.
- Pooled cohorts include baseline and one follow-up round. The mean follow-up time is 8.50 years (range: 1.0–27.7).
- We have pooled cardio-metabolic risk factors: anthropometrics, blood pressure, lipid and diabetes biomarkers, and non-fatal (stroke, myocardial infarction, revascularization) and fatal (stroke, myocardial infarction, revascularization, sudden death) cardio-vascular outcomes.
- Currently, data are not available for collaborations outside the consortium.

Supplementary Data

Supplementary data are available at IJE online.

Funding

Strategic Award, Wellcome Trust-Imperial College Centre for Global Health Research (100693/Z/12/Z). Imperial College London Wellcome Trust Institutional Strategic Support Fund [Global Health Clinical Research Training Fellowship] (294834/Z/16/Z ISSF ICL). R.C.-L. is supported by a Wellcome Trust International Training Fellowship (214185/Z/18/Z).

Acknowledgements

We thank Prof Sarah Lewington for comments and recommendations on an early version of this manuscript.

Conflict of Interest

None declared. The funders had no role in study design, data collation and analysis, decision to publish, or preparation of the manuscript. The authors alone are responsible for the views expressed in this paper; these do not necessarily represent the views, decisions, or policies of the institutions with which the authors are affiliated.

References

1. Kruk ME, Gage AD, Joseph NT, Danaei G, Garcia-Saiso S, Salomon JA. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries. Lancet 2018;392:2203–212.
2. Atun R, de Andrade LO, Almeida G et al. Health-system reform and universal health coverage in Latin America. Lancet 2015; 385:1230–247.
3. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52.

4. O’Donnell MJ, Chin SL, Rangarajan S et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016;388:761–75.

5. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 2017;390:2627–642.

6. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017;389:37–55.

7. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016;387:1513–530.

8. GBD 2016 Brazil Collaborators. Burden of disease in Brazil, 1990–2016: a systematic subnational analysis for the Global Burden of Disease Study 2016. Lancet 2018;392:760–75.

9. Stevens G, Dias RH, Thomas KJ et al. Characterizing the epidemiological transition in Mexico: national and subnational burden of diseases, injuries, and risk factors. PLoS Med 2008;5:e125.

10. James SL, Abate D, Abate KH et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789–858.

11. Kyu HH, Abate D, Abate KH et al. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1859–922.

12. Roth GA, Abate D, Abate KH et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736–788.

13. Friedenreich CM. Commentary: improving pooled analyses in epidemiology. Int J Epidemiol 2002;31:86–7.

14. Carrillo-Larco RM, Miranda JJ, Kengne AP. Data pooling efforts in Africa and Latin America. Lancet Glob Health 2017;5:e37.

15. Wormser D, Kaproke S, Di Angelantonio E et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011;377:1085–095.

16. Whitlock G, Lewington S, Sherliker P et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083–096.

17. Singh GM, Danaei G, Farzadfar F et al. The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One 2013;8:e65174.

18. Woodward M, Huxley R, Ueshima H, Fang X, Kim HC, Lam TH. The Asia pacific cohort studies collaboration: a decade of achievements. Glob Heart 2012;7:343–51.

19. Woodward M, Barzi F, Martiníuk A et al. Cohort profile: the Asia Pacific Cohort Studies Collaboration. Int J Epidemiol 2006;35:412–416.

20. NCD Risk Factor Collaboration (NCD-RisC). http://ncdrisrc.org/index.html.

21. Farzadfar F, Finucane MM, Danaei G et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011;377:578–86.

22. Lajous M, Ortiz-Panozo E, Monge A et al. Cohort Profile: The Mexican Teachers’ Cohort (MTC). Int J Epidemiol 2017;46:e10.

23. Ortiz-Panozo E, Yunes-Diaz E, Lajous M, Romieu I, Monge A, Lopez-Ridaura R. Validity of self-reported anthropometry in adult Mexican women. Salud Publica Mex 2017;59:266–75.

24. Rubinstein AL, Irazola VE, Poggio R et al. Detection and follow-up of cardiovascular disease and risk factors in the Southern Cone of Latin America: the CESCAS I study. BMJ Open 2011;1:e000126.

25. Prina AM, Acosta D, Acosta I et al. Cohort Profile: The 10/66 study, Int J Epidemiol 2017;46:406.

26. Prince M, Ferri CP, Acosta D et al. The protocols for the 10/66 dementia research group population-based research programme. BMC Public Health 2007;7:165.

27. Miranda JJ, Bernabe-Ortiz A, Smeeth L, Gilman RH, Checkley W. Addressing geographical variation in the progression of noncommunicable diseases in Peru: the CRONICAS cohort study protocol. BMJ Open 2012;2:e000610.

28. Pinto G, Beltran-Sanchez H. Prospective study of the link between overweight/obesity and diabetes incidence among Mexican older adults: 2001–2012. Salud Publica Mex 2015;57:15–21.

29. Puerto Rican Elderly: Health Conditions (PREHCO). http://prehco.rcm.upr.edu/.

30. Costa Rican Longevity and Healthy Aging Study (CRELES). http://www.creles.berkeley.edu/.

31. Campos Cavalcanti A, Oliveira Guerra R. Influence of economic development on the incidence of diabetes: the CESCAS I study. PLoS One 2013;8:e65174.

32. Egan KJ, von Schantz M, Negrao AB et al. Commentary: improving pooled analyses in epidemiology. Int J Epidemiol 2002;31:86–7.

33. Campos Cavalcanti A, Oliveira Guerra R. Influence of Biopsychosocial Factors on the Survival of the Elderly in Northeast Brazil—A Prospective Study. Curr Gerontol Geriatr Res 2010;2010:1–8.

34. Egan Kj, von Schantz M, Negrao AB et al. Cohort profile: the Baependi Heart Study—a family-based, highly admixed cohort study in a rural Brazilian town. BMJ Open 2016;6:e011598.

35. Pereira AC, Mota GF, Cunha RS, Herbenhoff FL, Mill JG, Krieger JE. Angiotensinogen 235T allele “dosage” is associated with blood pressure phenotypes. Hypertension 2003;41:25–30.
34. Ueda P, Woodward M, Lu Y et al. Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys. Lancet Diabetes Endocrinol 2017;5:196–213.

35. WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health 2019.

36. Bautista LE, Casas JP, Herrera VM et al. The Latin American Consortium of Studies in Obesity (LASO). Obes Rev 2009;10:364–70.

37. Miranda JJ, Herrera VM, Chirinos JA et al. Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO). PLoS One 2013;8:e54036.

38. Miranda JJ, Gilman RH, Smeeth L. Differences in cardiovascular risk factors in rural, urban and rural-to-urban migrants in Peru. Heart 2011;97:787–96.

39. Carrillo-Larco RM, Ruiz-Alejos A, Bernabé-Ortiz A, Gilman RH, Smeeth L, Miranda JJ. Cohort Profile: The PERU MIGRANT Study-A prospective cohort study of rural dwellers, urban dwellers and rural-to-urban migrants in Peru. Int J Epidemiol 2017;46:1752f.

40. Ferguson TS, Francis DK, Tulloch-Reid MK, Younger NO, McFarlane SR, Wilks RJ. An update on the burden of cardiovascular disease risk factors in Jamaica: findings from the Jamaica Health and Lifestyle Survey 2007-2008. West Indian Med J 2011;60:422–28.